Meta-analysis by the Program on the Surgical Control of the Hyperlipidemias (POSCH) investigators.
作者信息
Gould A L, Cariski A T
出版信息
Ann Surg. 1998 Feb;227(2):314-6. doi: 10.1097/00000658-199802000-00031.
Abstract
摘要
相似文献
1
Meta-analysis by the Program on the Surgical Control of the Hyperlipidemias (POSCH) investigators.高脂血症外科治疗项目（POSCH）研究人员进行的荟萃分析。
Ann Surg. 1998 Feb;227(2):314-6. doi: 10.1097/00000658-199802000-00031.
2
Gender-based mortality follow-up from the Program on the Surgical Control of the Hyperlipidemias (POSCH) and meta-analysis of lipid intervention trials. Women in POSCH and other lipid trials.来自血脂异常外科治疗项目（POSCH）的性别特异性死亡率随访及脂质干预试验的荟萃分析。POSCH及其他脂质试验中的女性。
Ann Surg. 1996 Oct;224(4):486-98; discussion 498-500. doi: 10.1097/00000658-199610000-00007.
3
Clinical trial assessment of lipid-acting drugs in diabetic patients.糖尿病患者中脂质作用药物的临床试验评估。
Am J Cardiol. 1998 Apr 23;81(8A):58F-59F. doi: 10.1016/s0002-9149(98)00265-3.
4
[BECAIT [Bezafibrate Coronary Atherosclerosis Intervention Trial]].[贝扎贝特冠状动脉粥样硬化干预试验]
Nihon Rinsho. 2001 Mar;59 Suppl 3:433-5.
5
Women in the POSCH trial. Effects of aggressive cholesterol modification in women with coronary heart disease. The POSCH Group. Program on the Surgical Control of the Hyperlipidemias.“冠心病药物治疗计划（POSCH）试验中的女性。积极胆固醇调整对冠心病女性的影响。POSCH研究小组。高脂血症外科治疗计划。”
Ann Surg. 1992 Oct;216(4):389-98; discussion 398-400. doi: 10.1097/00000658-199210000-00001.
6
Inclusion of lipoprotein subfractions among efficacy parameters.将脂蛋白亚组分纳入疗效参数之中。
Am J Cardiol. 1998 Apr 23;81(8A):52F-55F. doi: 10.1016/s0002-9149(98)00263-x.
7
Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events.
Curr Atheroscler Rep. 2003 Sep;5(5):418-22. doi: 10.1007/s11883-003-0014-1.
8
[Probucol].[普罗布考]
Nihon Rinsho. 2001 Mar;59 Suppl 3:631-6.
9
Program on the Surgical Control of the Hyperlipidemias (POSCH): design and methodology. POSCH Group.高脂血症外科治疗项目（POSCH）：设计与方法。POSCH研究小组
J Clin Epidemiol. 1989;42(12):1111-27. doi: 10.1016/0895-4356(89)90109-1.
10
[Coronary arteriosclerosis and lipid metabolism (hyperlipemia)].
Nihon Rinsho. 2003 Apr;61 Suppl 4:69-74.
本文引用的文献
1
Gender-based mortality follow-up from the Program on the Surgical Control of the Hyperlipidemias (POSCH) and meta-analysis of lipid intervention trials. Women in POSCH and other lipid trials.来自血脂异常外科治疗项目（POSCH）的性别特异性死亡率随访及脂质干预试验的荟萃分析。POSCH及其他脂质试验中的女性。
Ann Surg. 1996 Oct;224(4):486-98; discussion 498-500. doi: 10.1097/00000658-199610000-00007.
2
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.普伐他汀对胆固醇水平正常的心肌梗死患者冠状动脉事件的影响。胆固醇与再发事件试验研究人员。
N Engl J Med. 1996 Oct 3;335(14):1001-9. doi: 10.1056/NEJM199610033351401.
3
Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S).降低冠状动脉事件风险：来自斯堪的纳维亚辛伐他汀生存研究（4S）的证据。
Am J Cardiol. 1995 Sep 28;76(9):64C-68C. doi: 10.1016/s0002-9149(99)80473-1.
4
Meta-analysis in clinical trials.临床试验中的荟萃分析。
Control Clin Trials. 1986 Sep;7(3):177-88. doi: 10.1016/0197-2456(86)90046-2.
5
Test of effect of lipid lowering by diet on cardiovascular risk. The Minnesota Coronary Survey.饮食降脂对心血管风险影响的试验。明尼苏达冠心病调查。
Arteriosclerosis. 1989 Jan-Feb;9(1):129-35. doi: 10.1161/01.atv.9.1.129.
6
Bias in the one-step method for pooling study results.合并研究结果的一步法中的偏倚。
Stat Med. 1990 Mar;9(3):247-52. doi: 10.1002/sim.4780090307.
7
Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia.洛伐他汀扩展临床评估（EXCEL）研究结果。I. 对8245例中度高胆固醇血症患者调节血浆脂蛋白的疗效及不良事件情况
Arch Intern Med. 1991 Jan;151(1):43-9. doi: 10.1001/archinte.151.1.43.
Zotero 插件